Search results
Results from the WOW.Com Content Network
This treatment method is commonly linked with blood cancers like multiple myeloma, Hodgkin's lymphoma, and non-Hodgkin's lymphoma. It is also used in solid tumors such as germ cell tumors and certain high risk or recurrent breast cancers. Multiple myeloma, a type of plasma cell cancer [3] is an indication for HDC. Typically it follows stem cell ...
Peripheral blood stem cell transplantation (PBSCT), also called "Peripheral stem cell support", [1] is a method of replacing blood-forming stem cells.Stem cells can be destroyed through cancer treatments such as chemotherapy or radiation, as well as any blood-related diseases, such as leukemia, lymphoma, neuroblastoma and multiple myeloma. [2]
A 2016 study concluded that stem cell transplant is the preferred treatment for multiple myeloma. [107] There are two types of stem cell transplants to treat multiple myeloma. [108] In autologous hematopoietic stem-cell transplantation (ASCT) – the patient's stem cells are collected from the patient's blood. The patient is given high-dose ...
Stem-cell transplantation was pioneered using bone marrow-derived stem cells by a team at the Fred Hutchinson Cancer Research Center from the 1950s through the 1970s led by E. Donnall Thomas, whose work was later recognized with a Nobel Prize in Physiology or Medicine. Thomas' work showed that bone-marrow cells infused intravenously could ...
Stem-cell therapy uses stem cells to treat or prevent a disease or condition. [1] As of 2024, the only FDA-approved therapy using stem cells is hematopoietic stem cell transplantation. [2] [3] This usually takes the form of a bone marrow or peripheral blood stem cell transplantation, but the cells can also be derived from umbilical cord blood.
The cancer stem cell model, also known as the Hierarchical Model proposes that tumors are hierarchically organized (CSCs lying at the apex [6] (Fig. 3).) Within the cancer population of the tumors there are cancer stem cells (CSC) that are tumorigenic cells and are biologically distinct from other subpopulations [7] They have two defining features: their long-term ability to self-renew and ...
NF-Kappa-B Essential Modulator (NEMO) deficiency (Inhibitor of Kappa Light Polypeptide Gene Enhancer in B Cells Gamma Kinase deficiency) Hematologic diseases. Hemoglobinopathies; Sickle cell disease; β thalassemia major (Cooley's anemia) Anemias. Aplastic anemia. Diamond–Blackfan anemia; Fanconi anemia; Cytopenias. Amegakaryocytic ...
IRF4 is a master regulator of a number of cancer-promoting genes and is required for the survival of multiple myeloma. [9] Loss of IKZF1 and IKZF3 also results in increased expression and secretion of interleukin 2 and interferon gamma, which stimulates a local immune response from T cells and NK cells. [33]